表紙
市場調査レポート

新たな薬剤再構成システム

Novel Drug Reconstitution Systems, 2014 - 2024

発行 ROOTS ANALYSIS 商品コード 320319
出版日 ページ情報 英文 194 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
新たな薬剤再構成システム Novel Drug Reconstitution Systems, 2014 - 2024
出版日: 2014年12月02日 ページ情報: 英文 194 Pages
概要

薬剤再構成システム市場は今後10年間にわたって年率7.3%で成長する見込みです。新たな再構成システムは引き続き勢いを増し、市場全体の27%のシェアを獲得すると予測されています。

当レポートでは、成長する薬剤再構成システム市場について包括的な調査を提供しており、各システムの製品プロファイル、市場予測、近年の業界内における提携動向、技術開発動向、および主要企業のプロファイルなどについてまとめ、お届けいたします。

第1章 はじめに

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場概要

  • 本章の概要
  • 薬剤再構成システム
  • 製品フレームワーク

第5章 デュアルチャンバーシステム

  • 本章の概要
  • 市場情勢:製品の競争力:サプライヤーの力
  • 製品プロファイル
  • 詳細なプロファイル
  • 簡単な製品プロファイル

第6章 その他の新システム

  • 本章の概要
  • 製品プロファイル
  • 詳細なプロファイル
  • 簡単なプロファイル

第7章 ニードルフリーシステム

  • 本章の概要
  • 製品プロファイル
  • 詳細なプロファイル
  • 簡単なプロファイル
  • ケーススタディ:: ZetaJet (Bioject)

第8章 従来の再構成システム

  • 本章の概要
  • 市場情勢:製品の競争力・サプライヤーの力
  • 製品プロファイル
  • 詳細なプロファイル
  • 簡単なプロファイル

第9章 市場予測

  • 本章の概要
  • 予測手法
  • 全体的な薬剤再構成システム市場
  • 従来の再構成システム市場
  • 新たな再構成システム市場

第10章 認可薬・ワクチン

  • 本章の概要
  • 再構成処方用粉末におけるFDA認可済み薬剤
  • 粉末処方で認可されたワクチン

第11章 企業プロファイル

  • 本章の概要
  • Unilife Corporation
  • West Pharmaceutical Services
  • Medical, A Segment Of Becton Dickinson And Company
  • Sensile Medical AG
  • Ypsomed
  • Bioject Medical Technologies
  • Teva Pharmaceuticals
  • Vetter Pharma

第12章 業界の提携・技術発展

  • 本章の概要
  • 提携:主な業界における合意
  • 技術:発展のマッピング

第13章 SWOT分析

  • 本章の概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第14章 インタビュー原稿

  • 本章の概要
  • インタビュー1:Michael Reilly, Vice President Business Development, Integrity Bio
  • インタビュー2:Timothy Sullivan, President & CEO, Mystic Pharmaceuticals

第15章 結論

  • 従来型システムから新システムへの移行
  • 新システムの成長は多くの要因によって促進される
  • 従来型システムは近い将来その優位性を維持する見込み
  • 徐々に、新システムは具体的な市場シェアを獲得する見込み

第16章 付録1:表形式データ

第17章 付録2:企業リスト

図表リスト

目次
Product Code: RA10029

In today's pharmaceutical market, many drugs are supplied in powdered formulation because of their lower shelf life in liquid formulation. The drugs are formulated into powdered form by various processes such as lyophilisation or spray drying; these drugs are then reformulated into liquid form by mixing with a suitable diluent at the time of administration. The overall market of drug reconstitution systems is characterised by the presence of around 50 devices (both conventional and novel). The primary goal of these systems is to provide a hassle free reconstitution process in minimal number of steps. In addition, these systems also aim to provide an optimal protection from needlestick injuries to both the patients and healthcare providers.

Conventional drug reconstitution systems, including Vial Adaptors, Vial to Vial Systems, Direct Connection to Vial Systems and a few others, currently dominate the market. Some of these systems were developed nearly two decades ago and have gained a significant share of the market overtime. In addition, the use of traditional hypodermic needles for reconstituting the drug using a diluent vial is still widespread, especially in the developing countries. However, with new needlestick injuries prevention laws being implemented, along with rising approvals for biologic drugs, novel reconstitution systems such as Dual Chamber Systems are expected to be more popular and preferred option. A number of these novel systems make the process as easy as the push of a button in a much more safer and accurate manner.

Though the market for such novel devices is currently at nascent stage, there are several devices available for investigational use. The technology used in novel systems is likely to play an important part in enhancing the safety, patient compliance and ease of use. When ready, these devices are likely to have a significant impact on the overall market landscape.

Synopsis:

The ‘Novel Drug Reconstitution Systems, 2014-2024 Market' report provides a comprehensive study of the growing market of drug reconstitution systems. As mentioned earlier, this includes not only the conventional systems such as Vial Adaptors, Vial to Vial Systems but also novel systems such as Dual Chamber Systems. Due to an increasing number of biologics and the growing trend towards self-administration of drugs, novel drug reconstitution devices are becoming a key focus area for medical device manufacturers. The focus of this study is primarily to understand the governing trends and the likely future evolution of these devices over the next decade.

The report covers various aspects such as market developments, recent partnerships and our opinion on the likely drivers which will influence the industry's evolution. In addition, we have provided a holistic view of the market landscape including detailed profiles of leading devices, key features and their comparative position vis-à-vis other devices. Innovations in design and advanced safety mechanisms will continue to present encouraging prospects to device manufacturers in the years ahead.

In addition to the key benefits and the likely market drivers, this study also highlights some of the challenges associated with the use and implementation of these devices. Regular modifications in design and incorporation of safety features present operational challenges to the manufacturers. Cost is another factor that can significantly restrain the market, especially in the case of novel reconstitution systems. However, with the entrance of more devices in the market, prices are expected to come down; this, in turn, will result in a higher uptake of such systems.

The report also includes a special case study on drugs and vaccines requiring reconstitution prior to administration. We have looked at the specific indications, therapeutic areas and mode of administration of these powdered formulations.

The study provides short-midterm and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research.

Example Highlights:

  • 1. We expect that the overall market for drug reconstitution systems is likely to grow at an annualised rate of 7.3% over the coming decade. Novel reconstitution systems will continue to gain ground; by 2024, we expect them to contribute a significant share (27%) to the overall market.
  • 2. Increased venture capital interest is expected to drive additional resources to fund future development. Other drivers include the growing presence of lyophilised drugs, focus on self-administration, convenient disposal, applicability to mass immunisation / vaccination programmes and customisation options as per end-user requirements.
  • 3. Specific pockets of growth include ‘closed systems', which are expected to rise significantly as more number of chemotherapeutics receive approval in the near future.
  • 4. The market is characterised by the presence of various established players such as West Pharmaceutical Services, Becton Dickinson along with emerging firms such as Unilife Corporation, Sensile Medical, Integrity Bio, Mystic Pharmaceuticals. Emergence of small companies is expected to foster ongoing innovation in the area.
  • 5. The increasing number of partnerships is evident of the fact that the leading companies actively look up to these smaller companies for licensing the technology and use their own global presence to make the technology widely available.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 provides an executive summary of major highlights captured in the report. It offers a high level view on the likely future of drug reconstitution systems market.

Chapter 3 provides a general introduction to the drug reconstitution process. It covers the advantages of advanced reconstitution systems over conventional systems including likely benefits to both the patients and the manufacturers.

Chapter 4 provides a comprehensive analysis of the current market of drug reconstitution systems. It lists 50 devices that can be used to carry out reconstitution of powdered drugs, categorising them into the various sub-types (Vial Adaptors, Vial to Vial Systems, Direct Connection to Vial Systems, Dual Chamber Systems, Closed Systems and Needle Free Systems), mode of delivery and the nature of the device (disposable / reusable).

Chapter 5 provides detailed analysis on Dual Chamber Systems that are used for reconstitution of lyophilised drugs. We have presented a 2 X 2 matrix to compare the product competitiveness and supplier power of several devices belonging to this category. The chapter also provides detailed profiles of a number of Dual Chamber Systems which are currently available either commercially or for investigational use.

Chapter 6 focuses on other novel drug reconstitution systems. As in the last chapter, we have provided detailed profiles and highlighted key features of some of the upcoming devices in this category.

Chapter 7 focuses on Needle Free Reconstitution Systems. Most of these systems are used for infusion purposes. In addition to the detailed profiles of such systems, we have also included a special case study on ZetaJetTM, an advanced spring powered system that is designed to deliver vaccines and injectable medication either subcutaneously or intramuscularly.

Chapter 8 focuses on 24 conventional reconstitution systems which were identified during the course of this study. For these Vial Adaptors, Direct Connection to Vial Systems and Closed Systems, we have done a 2 X 2 matrix to compare the product competitiveness with respective supplier power. As in the earlier chapters, we have also profiled a number of these devices.

Chapter 9 highlights the likely future evolution of drug reconstitution systems market over the next ten years. We have done separate analysis for both conventional and novel reconstitution systems till the year 2024.

Chapter 10 provides information on FDA approved drugs and vaccines which are supplied in powdered formulation. We have analysed the product landscape highlighting the popular therapeutic areas and the mode of drug administration.

Chapter 11 includes the detailed profiles of some of the major players in the drug reconstitution systems market. For each company, we have covered details on financial performance, product portfolio, recent developments and future growth plans.

Chapter 12 captures the recent developments which have influenced the drug reconstitution systems market. It includes the agreements / partnerships that have been inked between different stakeholders. We have also provided a technology evolution roadmap clearly depicting the key milestones which have shaped the industry thus far.

Chapter 13 provides the SWOT analysis of drug reconstitution systems market giving strategic insights to the major factors that have contributed to the growth of this market. It also highlights the weaknesses and threats that can negatively impact the growth.

Chapter 14 is a collection of interview transcripts; for the purposes of this study, we held discussions with several experts to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 15 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 17 is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope Of The Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Defining Drug Reconstitution
  • 3.2. History
  • 3.3. Human Factors Driving The Growth Of Advanced Reconstitution Devices
  • 3.4. Traditional Method vs. Novel Reconstitution Methods
  • 3.5. Challenges With Traditional Reconstitution Process
  • 3.6. Benefits Of Advanced Reconstitution Systems For Patients
  • 3.7. Benefits For Manufacturers
  • 3.8. Factors To Be Considered By Manufacturers For Choosing The Right Reconstitution System
  • 3.9. Common Reconstitution Systems

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Drug Reconstitution Systems
    • 4.2.1. Novel Reconstitution Systems Are Gaining Ground
    • 4.2.2. Most Of The Reconstitution Systems Are Disposable
    • 4.2.3. Injectable Devices Continue To Dominate
  • 4.3. Product Framework

5. DUAL CHAMBER SYSTEMS

  • 5.1. Chapter Overview
  • 5.2. Market Landscape: Product Competitiveness And Supplier Power
  • 5.3. Product Profiles
  • 5.4. Detailed Profiles
    • 5.4.1. LyoTwistTM (Ypsomed)
      • 5.4.1.1. Introduction
      • 5.4.1.2. Specifications Of Devices Under LyoTwistTM Platform
      • 5.4.1.3. Usage / Mechanism
      • 5.4.1.4. Advantages / Features
      • 5.4.1.5. Benefits To The End-user
      • 5.4.1.6. Current Status
    • 5.4.2. EZMixTM (Unilife)
      • 5.4.2.1. Introduction
      • 5.4.2.2. Usage / Mechanism
      • 5.4.2.3. Advantages / Features
      • 5.4.2.4. Benefits For Customers
      • 5.4.2.5. Current Status
    • 5.4.3. Airless DCTM (Duoject)
      • 5.4.3.1. Introduction
      • 5.4.3.2. Structure
      • 5.4.3.3. Usage / Mechanism
      • 5.4.3.4. Advantages / Features
    • 5.4.4. SafeClickTM Lyo (Future Injection Technologies)
      • 5.4.4.1. Introduction
      • 5.4.4.2. Usage / Mechanism
      • 5.4.4.3. Advantages / Features
      • 5.4.4.4. Benefits To The End-user
  • 5.5. Brief Product Profiles
    • 5.5.1. Lyo-DCPS (Arte Corporation & ProJect Pharmaceutics)
    • 5.5.2. BD™ Liquid / Dry Injector (Becton Dickinson)
    • 5.5.3. Genotropin Miniquick (Vetter Pharma)
    • 5.5.4. ChaSyrTM DDS (Global Holdings)

6. OTHER NOVEL SYSTEMS

  • 6.1. Chapter Overview
  • 6.2. Product Profiles
  • 6.3. Detailed Profiles
    • 6.3.1. SenseLyo (Sensile Medical)
      • 6.3.1.1. Introduction
      • 6.3.1.2. Usage / Mechanism
      • 6.3.1.3. Advantages / Features
    • 6.3.2. Flexi-Q DV (Elcam Medical)
      • 6.3.2.1. Introduction
      • 6.3.2.2. Parts Of Flexi-Q DV
      • 6.3.2.3. Usage / Mechanism
      • 6.3.2.4. Advantages / Features
      • 6.3.2.5. Current Status
    • 6.3.3. Pen-PrepTM EVO (Duoject)
      • 6.3.3.1. Introduction
    • 6.3.4. Usage / Mechanism
      • 6.3.4.1. Advantages / Features
  • 6.4. Brief Profiles
    • 6.4.1. LyoTipTM (Integrity Bio)
    • 6.4.2. VRx2TM (Mystic Pharmaceuticals)
    • 6.4.3. LyoKit (Recon Therapeutics)
    • 6.4.4. Inter-Vial / Inter Vial Plus (Duoject)
    • 6.4.5. PenJet® (PenJet Corporation)
    • 6.4.6. BD PhaSealTM System (Becton Dickinson)

7. NEEDLE FREE SYSTEMS

  • 7.1. Chapter Overview
  • 7.2. Product Profiles
  • 7.3. Detailed Profiles
    • 7.3.1. Vial2Bag® (West Pharmaceutical Services)
      • 7.3.1.1. Introduction
      • 7.3.1.2. Usage / Mechanism
      • 7.3.1.3. Advantages / Features
      • 7.3.1.4. Current Status
    • 7.3.2. Mapset® (Technoflex)
      • 7.3.2.1. Introduction
      • 7.3.2.2. Usage / Mechanism
      • 7.3.2.3. Advantages / Features:
  • 7.4. Brief Profiles
    • 7.4.1. DianaTM (ICU Medical)
    • 7.4.2. Macopharma
  • 7.5. Case Study: ZetaJet® (Bioject)
    • 7.5.1.1. Introduction
    • 7.5.1.2. Product Specifications
    • 7.5.1.3. Usage / Mechanism
    • 7.5.1.4. Advantages / Features
    • 7.5.1.5. Convenience
    • 7.5.1.6. Safety
    • 7.5.1.7. Current Status

8. CONVENTIONAL RECONSTITUTION SYSTEMS

  • 8.1. Chapter Overview
  • 8.2. Market Landscape: Product Competitiveness And Supplier Power 8.3. Product Profiles
  • 8.4. Detailed Profiles
    • 8.4.1. Tevadaptor (Teva Medical)
      • 8.4.1.1. Introduction
      • 8.4.1.2. Components
      • 8.4.1.3. Material Specifications
      • 8.4.1.4. Usage / Mechanism
      • 8.4.1.5. Advantages / Features
      • 8.4.1.6. Current Status
    • 8.4.2. Smart-Rod XR (Duoject)
      • 8.4.2.1. Introduction
      • 8.4.2.2. Usage / Mechanism
      • 8.4.2.3. Advantages / Features
      • 8.4.2.4. Current Status
    • 8.4.3. SmartMix™ (Yukon Medical)
      • 8.4.3.1. Introduction
      • 8.4.3.2. Usage / Mechanism
      • 8.4.3.3. Advantages / Features
      • 8.4.3.4. Current Status
  • 8.5. Brief Profiles
    • 8.5.1. MixJect® (West Pharmaceuticals)
    • 8.5.2. FILLChoice™ Dose bag (Haemopharm)
    • 8.5.3. Mix2Vial® (West Pharmaceutical Services)
    • 8.5.4. Bioject® Drug Reconstitution System (Bioject)
    • 8.5.5. CodanCyto® (Codan)
    • 8.5.6. Clip'n'Ject (West Pharmaceutical Services)

9. MARKET FORECAST

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology
  • 9.3. Overall Drug Reconstitution Systems Market, 2014-2024
  • 9.4. Conventional Reconstitution Systems Market, 2014-2024
  • 9.5. Novel Reconstitution Systems Market 2014-2024

10. APPROVED DRUGS AND VACCINES

  • 10.1. Chapter Overview
  • 10.2. Drugs Approved By FDA In Powder For Reconstitution Formulation
    • 10.2.1. Distribution By Year
    • 10.2.2. Distribution By Therapeutic Areas
    • 10.2.3. Distribution By Mode Of Administration
  • 10.3. Vaccines Approved In Powdered Formulation

11. COMPANY PROFILES

  • 11.1. Chapter Overview
  • 11.2. Unilife Corporation
    • 11.2.1. Overview And Background
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
      • 11.2.3.1. Unifill Platform Of Prefilled Syringes
      • 11.2.3.2. EZMix Platform Of Dual-Chamber Syringes (Drug Reconstitution Delivery Systems)
      • 11.2.3.3. Auto-Injector Platform
      • 11.2.3.4. Wearable Injector Platform
      • 11.2.3.5. Ocular Delivery Systems
      • 11.2.3.6. Novel Delivery Systems
    • 11.2.4. Recent Developments
    • 11.2.5. Future Growth Plans
  • 11.3. West Pharmaceutical Services
    • 11.3.1. Overview And Background
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
      • 11.3.3.1. Marketed Products
      • 11.3.3.2. Pipeline Products
    • 11.3.4. Recent Developments
    • 11.3.5. Future Growth Plans
  • 11.4. BD Medical, A Segment Of Becton Dickinson And Company
    • 11.4.1. Overview And Background
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
      • 11.4.3.1. Marketed Products
      • 11.4.3.2. Pipeline Products
    • 11.4.4. Recent Developments
    • 11.4.5. Future Growth Plans
  • 11.5. Sensile Medical AG
    • 11.5.1. Overview And Background
    • 11.5.2. Product Portfolio
    • 11.5.3. Technology Portfolio
    • 11.5.4. Recent Developments
    • 11.5.5. Future Growth Plans
  • 11.6. Ypsomed
    • 11.6.1. Overview And Background
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Recent Developments
    • 11.6.5. Future Growth Plans
  • 11.7. Bioject Medical Technologies
    • 11.7.1. Overview And Background
    • 11.7.2. Product Portfolio
    • 11.7.3. Technology Portfolio
    • 11.7.4. Recent Developments
    • 11.7.5. Future Growth Plans
  • 11.8. Teva Pharmaceuticals
    • 11.8.1. Overview And Background
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Recent Developments
    • 11.8.5. Future Growth Plans
  • 11.9. Vetter Pharma
    • 11.9.1. Company Overview
    • 11.9.2. Lyo-Ject Glass Prefilled Systems
    • 11.9.3. Safety Systems: Add on Devices
    • 11.9.4. Recent Developments

12. INDUSTRY PARTNERSHIPS AND TECHNOLOGICAL EVOLUTION

  • 12.1. Chapter Overview
  • 12.2. Partnerships: Key Industry Agreements
  • 12.3. Technology: Mapping The Evolution

13. SWOT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Strengths
  • 13.3. Weaknesses
  • 13.4. Opportunities
  • 13.5. Threats

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Interview 1: Michael Reilly, Vice President Business Development, Integrity Bio
  • 14.3. Interview 2: Timothy Sullivan, President & CEO, Mystic Pharmaceuticals

15. CONCLUSION

  • 15.1. The Transition From Conventional Systems To Novel Systems
  • 15.2. Growth Of Novel Systems Will Be Driven By A Number Of Factors
  • 15.3. Conventional Systems Likely To Continue Their Dominance In The Near Future
  • 15.4. Over Time, Novel Systems Will Account For A Tangible Market Share

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES

List of Figures:

  • Figure 4.1: Classification Of Reconstitution Systems
  • Figure 4.2: Drug Reconstitution Systems: Distribution by Usability
  • Figure 4.3: Drug Reconstitution Systems: Distribution By Mode Of Administration
  • Figure 4.4: Product Map Of 50 Drug Reconstitution Devices
  • Figure 5.1: Market Landscape Of Dual Chamber Systems: Product Competitiveness And Supplier Power
  • Figure 5.2: Dual Chamber Systems: Product Framework
  • Figure 6.1: Other Novel Systems: Product Framework
  • Figure 7.1: Needle Free Systems: Product Framework
  • Figure 8.1: Market Landscape Of Conventional Systems: Product Competitiveness And Supplier Power
  • Figure 8.2: Conventional Systems: Product Framework
  • Figure 9.1: Overall Drug Reconstitution Systems Market, Short-Midterm (2014-2019): Base Scenario (USD Billion)
  • Figure 9.2: Overall Drug Reconstitution Systems Market, Long Term (2019-2024): Base Scenario (USD Billion)
  • Figure 9.3: Conventional Reconstitution Systems Market, Short-Midterm (2014-2019): Base Scenario (USD Billion)
  • Figure 9.4: Conventional Reconstitution Systems Market, Long Term (2019-2024): Base Scenario (USD Billion)
  • Figure 9.5: Conventional Reconstitution Systems, 2014-2024: Distribution by Type of System
  • Figure 9.6: Novel Reconstitution Systems Market, Short-Midterm (2014-2019): Base Scenario (USD Billion)
  • Figure 9.7: Novel Reconstitution Systems Market, Long Term (2019-2024): Base Scenario (USD Billion)
  • Figure 9.8: Novel Reconstitution Systems, 2014-2024: Distribution By Type of System
  • Figure 10.1: Drugs In Powdered Formulation: Distribution By Year Of Approval
  • Figure 10.2: Drugs Approved In Powdered Formulation: Distribution By Therapeutic Area
  • Figure 10.3: Drugs Approved In Powdered Formulation: Distribution By Mode Of Administration
  • Figure 11.1: Unilife Corporation: Revenue, 2011 - 2013 (USD ‘000)
  • Figure 11.2: West Pharmaceutical Services: Revenue By Business Divisions, 2011-2013(USD Million)
  • Figure 11.3: BD Medical: Revenue By Business Divisions, 2011-2013 (USD Billion)
  • Figure 11.4: Ypsomed: Revenue By Business Divisions, 2011-2013 (CHF Million)
  • Figure 11.5: Teva Pharmaceuticals: Revenue By Business Divisions, 2011 - 2013 (USD Billion)
  • Figure 12.1: Drug Reconstitution Systems: Technological Evolution Map
  • Figure 15.1: Drug Reconstitution Systems Market: Comparative Market Evolution Scenarios, 2014, 2019 and 2024 (USD Billion)

List of Tables:

  • Table 4.1: List Of Drug Reconstitution Systems
  • Table 5.1: LyoTwistTM: Key Features Of Variants
  • Table 8.1: Materials Used In Tevadaptor System
  • Table 9.1: Conventional Systems: Composition Of Subcategories
  • Table 10.1: List Of Drugs In ‘Powder For Reconstitution' Formulation
  • Table 10.2: Vaccines In Powder Formulation
  • Table 11.1: Ypsomed: Marketed Products
  • Table 11.2: Bioject: Product Pipeline
  • Table 12.1: Recent Agreements
  • Table 13.1: SWOT Analysis
  • Table 16.1: Classification Of Reconstitution Systems
  • Table 16.2: Distribution Of The Reconstitution Systems On The basis Of Usability
  • Table 16.3: Distribution Of Drug Reconstitution Systems On The basis Of their use
  • Table 16.4: Overall Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 16.5: Overall Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 16.6: Overall Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 16.7: Overall Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 16.8: Overall Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 16.9: Overall Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 16.10: Conventional Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 16.11: Conventional Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 16.12: Conventional Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 16.13: Conventional Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 16.14: Conventional Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 16.15: Conventional Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 16.16: Novel Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 16.17: Novel Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 16.18: Novel Drug Reconstitution Systems Market (USD BN), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 16.19: Novel Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 16.20: Novel Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 16.21: Novel Drug Reconstitution Systems Market (USD BN), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 16.22: Year-wise Distribution Of Approved Drugs In Powdered Formulation, Since 2010
  • Table 16.23: Classification Of Approved Drugs Based On Therapeutic Area
  • Table 16.24: Distribution Of Approved Drugs By Mode Of Administration
  • Table 16.25: Revenues, Unilife Corporation, FY 2011-2013 (USD ‘000)
  • Table 16.26: West Pharmaceutical Services, 2011-2013, Sales By Business Divisions (USD Million, %)
  • Table 16.27: BD Medical, 2011-2013, Sales By Business Divisions (USD Billion)
  • Table 16.28: Ypsomed, 2011-2013, Sales By Business Divisions (CHF Million)
  • Table 16.29: Revenue Distribution In Different Segments Of Teva (USD Billion, 2011-2013)
  • Table 16.30: Drug Reconstitution Systems Market (USD Billion): Comparative Scenarios; 2014, 2019 and 2024

List of Companies:

The following companies have been mentioned in this study:

  • 1. Acambis
  • 2. Adelphi Healthcare Packaging
  • 3. Allergan
  • 4. Amgen
  • 5. Amylin
  • 6. Arte Corporation
  • 7. AstraZeneca
  • 8. Auxilium Pharmaceuticals
  • 9. B. Braun Medical
  • 10. Baxter
  • 11. Becton Dickinson
  • 12. Biodel
  • 13. Biogen Idec
  • 14. Bioject
  • 15. Bracco Diagnostics Inc
  • 16. Bristol-Myers Squibb
  • 17. CareFusion
  • 18. Cato Software Solutions
  • 19. Cerexa
  • 20. Codan
  • 21. Crucell
  • 22. CSL Behring
  • 23. Daikyo Seiko
  • 24. Disetronic Group
  • 25. Dongbao
  • 26. Duoject
  • 27. Durata Therapeutics
  • 28. Elan Corporation (acquired by Perrigo)
  • 29. Elcam medical
  • 30. Eli Lilly
  • 31. Ferring Pharmaceuticals
  • 32. Flashmed Inc.
  • 33. Flextronics
  • 34. Fondaco PTE Ltd.
  • 35. Future injection technologies
  • 36. GenCell Biosystems
  • 37. Genentech
  • 38. Genzyme Corporation
  • 39. Gilead
  • 40. GlaxoSmithKline
  • 41. Global Holdings
  • 42. Globe Medical Tech.
  • 43. GTC BioTherapeutics
  • 44. Haemopharm
  • 45. Hikma
  • 46. ICU Medical
  • 47. Incepta Pharmaceuticals
  • 48. Infusion Solution Inc.
  • 49. Infusive Technologies
  • 50. Integrity Bio
  • 51. Ipsen Biopharm Limited
  • 52. Janssen Biotech
  • 53. Labrys Biologics
  • 54. Lundbeck
  • 55. Lupin Ltd.
  • 56. Macopharma
  • 57. MedImmune
  • 58. Medimop Medical Projects Ltd.
  • 59. Merck
  • 60. Microdose
  • 61. Millennium Pharmaceuticals
  • 62. MJ Biopharm
  • 63. Mystic Pharmaceuticals
  • 64. Navidea Biopharmaceuticals Inc.
  • 65. Novartis
  • 66. NPS Pharmaceuticals
  • 67. NuPathe
  • 68. Nycomed
  • 69. Octapharma
  • 70. Organon Teknika Corp LLC
  • 71. Penjet corporation
  • 72. Pfizer
  • 73. Pharming Group
  • 74. Pharmstandard
  • 75. Polfa Tarchomin
  • 76. Premier Inc.
  • 77. Progressive Medical Inc.
  • 78. ProJect Pharmaceutics
  • 79. Publix Super Markets
  • 80. Recon Therapeutics
  • 81. Roche Holdings
  • 82. Safety Syringes
  • 83. Sanofi
  • 84. scPharmaceuticals
  • 85. Sensile Medical
  • 86. Shire Pharmaceuticals
  • 87. SHL Medical
  • 88. Square Pharmaceuticals
  • 89. Technoflex
  • 90. Teva
  • 91. Theratechnologies
  • 92. Theravance
  • 93. UCB
  • 94. Unilife
  • 95. Vetter Pharma
  • 96. Watson Pharmaceuticals
  • 97. Weibel CDS AG
  • 98. West Pharma
  • 99. Ypsomed
  • 100. Yukon Medical
Back to Top